| 27 Octobre 2016
With 90.4% failure rate in R&D and, according to Stanford University, 85% of research resources being wasted due to exaggerations and frauds, some R&D managers and CEOs have already launched "Fully External R&D B plans", giving real and fair opportunities to clearly high potential non-dominant thinking to de-risk their businesses and generate truly novel integrated solutions for patients. They are fully convinced there is a solution!
Bio-Modeling Systems, is one of these few "fast-growing minority thinking" who has already proven that this is possible. We changed the discovery paradigm to create novel medical meanings from unreliable heterogeneous sources of data.
BMSystems, created in 2004 and profitable since 2006, thanks to our recurrent clients, is the world's first Mechanisms-Based Medicine company. Our patented collaborative discoveries already led to:
- A world's first in neurodegenerative diseases (publication) with 2 awards in the US and Europe.
- Pherecydes-Pharma: BMSystems' spin-off, MR infections therapies, publication, in Phase I/II,
- Theranexus, the CEA Life Sciences' spin-off exploiting the CEA/BMSystems' co-patent WO/2010/029131 in CNS therapies, Phase II entry of THN102, ODD from FDA.
- A novel combined treatment candidate using two existing drugs for Parkinson's disease ready for experimental validation cited in an international report.
- A CADI Discovery program on Alzheimer's disease that already explains some major unexplained clinical observations and confirms that "A beta" and "Tau" are unspecific consequences of the disease not the causes.
In-licensing new diagnostics or treatments is a priority for Pharma companies, but with a 90.4% failure rate making the right decision as soon as possible becomes critical to save time and money. We invented CADI Discovery, the world's first and to date only operational "Mechanisms-based Medicine" analytical platform that proposes robust decision making support for R&D and Business:
- GO-NO GO decision before product acquisition or for portfolio risk analysis.
- GO-NO GO decision before next development phase.
- R&D program Rescue for a program facing critical issues during its lifetime.
- Fully External R&D B plan program when the A plan cannot be rescued to discover novel diagnostics & therapies.
- Exploratory Discovery program to generate novel causal mechanism concepts and discover novel diagnostics & therapies.
Latest news: Theranexus, the CEA Life Sciences' spin-off, exploiting the CEA/BMSystems' copatent WO/2010/029131 in CNS therapeutics, received with its partners the support from the French Inter-ministry Fund for their project, Cx-COG. This ambitious project of US$ 3.6 million is on the clinical validation of the efficacy of product THN201 in the treatment of neurocognitive impairment caused by Alzheimer's disease. Download the official Theranexus' press release.
We warmly invite you to download our Short Presentation (recommended) or our Full Presentation with the working principles and the10 POCs exposed in details.
For more information: www.bmsystems.net
Author's LinkedIn Posts: https://www.linkedin.com/today/posts/manuelgea
I should be very happy if you accept to join my networks
